Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
9.12.2020 12:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Fund for Development Signs USD 15 Million Agreement with the Republic of Palau to Drive Local Economic Growth6.4.2026 22:01:00 EEST | Press release
The Saudi Fund for Development (SFD) today signed a USD 15 million development loan agreement with the Republic of Palau, marking the Fund’s first-ever development partnership in the Pacific island nation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406306007/en/ Saudi Fund for Development Signs USD 15 Million Agreement with the Republic of Palau to Drive Local Economic Growth (Photo: AETOSWire) The agreement was signed by H.E. Sultan Abdulrahman Al-Marshad, Chief Executive Officer of SFD, and H.E. Surangel S. Whipps Jr., President of the Republic of Palau during a ceremony in Palau’s capital, Ngerulmud. The USD 15 million development loan will be channeled through the National Development Bank of Palau. Designed to empower the local economy, the financing will support projects spearheaded by Palauan developers, businesses, and entrepreneurs. By aligning with Palau’s national priorities, the funds will catalyze high-im
Bureau Veritas Acquires Lotusworks, Reinforcing Its Position in Data Centers and Entering the Semiconductor Sector; This Establishes a New c.Eur 300 Million Growth Platform6.4.2026 21:00:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has signed an agreement to acquire Lotusworks, a global leader in mission‑critical assets commissioning and quality assurance and control. This strategic move will uniquely position the Buildings & Infrastructure Product Line to benefit from AI-driven construction investments. Headquartered in Ireland, Lotusworks is a leading provider of commissioning, quality assurance and quality control, calibration, maintenance, and construction management services for mission‑critical facilities for semiconductors manufacturers and data center owners. The Company operates in the United States and Europe, and employs 750 people including highly skilled experts, serving a diversified base of blue‑chip global clients, including hyperscalers and semiconductor manufacturers. Lotusworks’ activity is supported by long‑term frameworks, a strong multi‑year backlog, and recurring technical services in
Svante & Meadow Lake Tribal Council Partnership Agrees to Sell Microsoft 626,000 Tonnes of Carbon Removal Credits6.4.2026 18:00:00 EEST | Press release
Svante Technologies Inc. (Svante) and Meadow Lake Tribal Council (MLTC) announced today that North Star Carbon Solutions LP has entered into an offtake agreement with Microsoft to deliver 626,000 tonnes of durable carbon dioxide removal (CDR) credits to be delivered over 15 years from the North Star bioenergy with carbon capture and storage (BECCS) project in Saskatchewan, Canada. The project is being developed through a partnership between MLTC and Svante and will be co-located at the MLTC Bioenergy Centre in Meadow Lake. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406630377/en/ As part of the project, a new carbon capture plant will be established at the MLTC Bioenergy Centre, a renewable power generation facility supplied by sustainable waste biomass from the adjacent sawmill owned by MLTC and other local forest product mills. The new plant will be owned by North Star Carbon Solutions LP, a partnership between MLTC
Textron Aviation Names Five 2026 Top Hawk Recipients as Program Enters Its Second Decade of Workforce Impact6.4.2026 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced Brazos Valley Flight Services, Executive Air Taxi Corporation, Fairmont State University, Sterling Flight Training and Victors Aviation as its 2026 Top Hawk program recipients, continuing a legacy that has placed 55 factory-new Cessna Skyhawks in training environments since the program launched in 2015. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402481685/en/ Factory-new Cessna Skyhawks (Model 172) to take flight as Textron Aviation names five 2026 Top Hawk recipients—helping train the next generation of pilots Now entering its second decade, Top Hawk is one of the industry’s longest‑running manufacturer‑school partnerships. Designed to support aviation workforce development, the program loans custom‑branded, factory‑new Skyhawks to selected organizations for one year, giving students access to the world’s most popular training aircraft and help
The Spectrum of Global Cinema Unfolds in Jeonju: The 27th JEONJU International Film Festival6.4.2026 16:23:00 EEST | Press release
The 27th JEONJU International Film Festival (JIFF) is set to run from April 29 to May 8 in Jeonju, featuring 237 movies from 54 countries. Jeonju—the most authentic Korean city and a prominent tourist destination in Asia known for its tradition and cuisine—will host this year’s film festival under the slogan “Beyond the Frame.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406890043/en/ The 27th JEONJU International Film Festival will take place from April 29 to May 8 in Jeonju (Image: JEONJU CITY) Opening the 27th edition will be Kent Jones’s “Late Fame,” while the film “The Longest Night: Namtaeryong” directed by Kim Hyun-ji will close the festival. In addition, a special program honors the late Korean actor Ahn Sung-ki, who passed away last year. Titled “Special Focus: Ahn Sung-ki’s Memorable Films Yet Rarely Seen,” it showcases seven of his films to pay tribute to a distinguished acting career defined by ceaseless ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom